8576 - 8600 of 9139 Results
Title
Year
- Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial2023RESTRICTEDTitle: Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trialJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 114Issue #:Start Page: 105511End Page: 105511Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2023.105511Citation Count: 13
-
OPENTitle: Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique StudyJournal Name: MDM Policy & PracticePublisher: SAGE PublicationsVol: 6Issue #: 1Start Page: 2381468320978407End Page: 2381468320978407Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1177/2381468320978407Best OA location URL: https://journals.sagepub.com/doi/pdf/10.1177/2381468320978407Citation Count: 23
-
OPENTitle: The Experience of OFF Periods in Parkinson’s Disease: Descriptions, Triggers, and Alleviating FactorsJournal Name: Journal of Patient-Centered Research and ReviewsPublisher: Aurora Health Care, Inc.Vol: 8Issue #: 3Start Page: 232End Page: 238Publication Date:Open Access(OA) Status: OPENLicense: other-oaDOI - Digital Object Identifier: 10.17294/2330-0698.1836Best OA location URL: https://institutionalrepository.aah.org/cgi/viewcontent.cgi?article=1836&context=jpcrrCitation Count: 18
-
OPENTitle: The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variantsJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 35Issue #: 1Start Page: 266.e5End Page: 266.e14Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2013.07.013Best OA location URL: https://www.sciencedirect.com/science/article/pii/S0197458013003187Citation Count: 41
-
OPENTitle: A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's ResearchJournal Name: Disease Models & MechanismsPublisher: The Company of BiologistsVol:Issue #:Start Page: 1316End Page: 24Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1242/dmm.011940Best OA location URL: https://doi.org/10.1242/dmm.011940Citation Count: 40
-
OPENTitle: Remote Digital Monitoring for Medical Product DevelopmentJournal Name: Clinical and Translational SciencePublisher: WileyVol: 14Issue #: 1Start Page: 94End Page: 101Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1111/cts.12851Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cts.12851Citation Count: 22
-
OPENTitle: The hTH-GFP Reporter Rat Model for the Study of Parkinson's DiseaseJournal Name: PLoS ONEPublisher: Public Library of Science (PLoS)Vol: 9Issue #: 12Start Page: e113151End Page: e113151Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1371/journal.pone.0113151Best OA location URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0113151&type=printableCitation Count: 21
- Resource translocation drives 13C fractionation during recovery from disturbance in giant kelp, Macrocystis pyrifera2013RESTRICTEDTitle: Resource translocation drives 13C fractionation during recovery from disturbance in giant kelp, Macrocystis pyriferaJournal Name: Journal of PhycologyPublisher: WileyVol: 49Issue #: 5Start Page: 811End Page: 815Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1111/jpy.12099Citation Count: 21
-
OPENTitle: The Most Bothersome Aspects of Off Periods Reported by Individuals with Parkinson's DiseaseJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 7Issue #: 3Start Page: 284End Page: 292Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mdc3.12915Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.12915Citation Count: 20
-
OPENTitle: Patient-Centered Identification of Meaningful Regulatory Endpoints for Medical Devices to Treat Parkinson’s DiseaseJournal Name: MDM Policy & PracticePublisher: SAGE PublicationsVol: 6Issue #: 1Start Page: 23814683211021380End Page: 23814683211021380Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1177/23814683211021380Best OA location URL: https://journals.sagepub.com/doi/pdf/10.1177/23814683211021380Citation Count: 14
-
OPENTitle: Putting participants and study partners FIRST when clinical trials end earlyJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 18Issue #: 12Start Page: 2736End Page: 2746Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/alz.12732Best OA location URL: https://doi.org/10.1002/alz.12732Citation Count: 12
-
OPENTitle: Use of an Online Portal to Facilitate Clinical Trial Recruitment: A Preliminary Analysis of Fox Trial FinderJournal Name: Journal of Parkinson’s DiseasePublisher: SAGE PublicationsVol: 5Issue #: 1Start Page: 55End Page: 66Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-140522Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd140522?id=journal-of-parkinsons-disease%2Fjpd140522Citation Count: 14
-
OPENTitle: Insights into ancestral diversity in Parkinson’s disease risk: a comparative assessment of polygenic risk scoresJournal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 11Issue #: 1Start Page: 201End Page: 201Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41531-025-00967-4Best OA location URL: https://www.nature.com/articles/s41531-025-00967-4.pdfCitation Count: 5
- Baseline-dependency: How genotype and signaled delays influence amphetamine's effects on delay discounting2020RESTRICTEDTitle: Baseline-dependency: How genotype and signaled delays influence amphetamine's effects on delay discountingJournal Name: Pharmacology Biochemistry and BehaviorPublisher: Elsevier BVVol: 199Issue #:Start Page: 173070End Page: 173070Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.pbb.2020.173070Citation Count: 10
-
OPENTitle: Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson’s diseaseJournal Name: Journal of Biopharmaceutical StatisticsPublisher: Informa UK LimitedVol: 35Issue #: 5Start Page: 981End Page: 1000Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1080/10543406.2023.2170400Best OA location URL: https://doi.org/10.1080/10543406.2023.2170400Citation Count: 8
- Including People with Parkinson’s Disease in Clinical Study Design and Execution: A Call to Action2022OPENTitle: Including People with Parkinson’s Disease in Clinical Study Design and Execution: A Call to ActionJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 12Issue #: 4Start Page: 1359End Page: 1363Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-223190Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd223190?id=journal-of-parkinsons-disease%2Fjpd223190Citation Count: 15
-
OPENTitle: Beyond Alzheimer’s disease—translating biomarker insights across CNS diseasesJournal Name: Science Translational MedicinePublisher: American Association for the Advancement of Science (AAAS)Vol: 17Issue #: 823Start Page: eadr2511End Page: eadr2511Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1126/scitranslmed.adr2511Best OA location URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC13162155/Citation Count: 2
- Addition of Filgrastim (Neupogen) for Clozapine Rechallenge in the Case of Parkinson Disease Patient2017RESTRICTEDTitle: Addition of Filgrastim (Neupogen) for Clozapine Rechallenge in the Case of Parkinson Disease PatientJournal Name: Clinical NeuropharmacologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 40Issue #: 5Start Page: 233End Page: 234Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1097/wnf.0000000000000230Citation Count: 7
- Recruitment Strategies across the Spectrum of Neuronal Synuclein Disease2026RESTRICTEDTitle: Recruitment Strategies across the Spectrum of Neuronal Synuclein DiseaseJournal Name: Annals of NeurologyPublisher: WileyVol:Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/ana.78239Citation Count: 0
-
OPENTitle: Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral OrgansJournal Name: PLoS ONEPublisher: Public Library of Science (PLoS)Vol: 8Issue #: 11Start Page: e80705End Page: e80705Publication Date:Open Access(OA) Status: OPENLicense: cc0DOI - Digital Object Identifier: 10.1371/journal.pone.0080705Best OA location URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0080705&type=printableCitation Count: 187
-
OPENTitle: Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitorsJournal Name: Biochemical JournalPublisher: Portland Press Ltd.Vol: 473Issue #: 17Start Page: 2671End Page: 2685Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1042/bcj20160557Best OA location URL: https://portlandpress.com/biochemj/article-pdf/473/17/2671/687564/bj4732671.pdfCitation Count: 182
-
OPENTitle: Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophilsJournal Name: Biochemical JournalPublisher: Portland Press Ltd.Vol: 475Issue #: 1Start Page: 23End Page: 44Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1042/bcj20170803Best OA location URL: https://portlandpress.com/biochemj/article-pdf/475/1/23/694098/bcj-2017-0803.pdfCitation Count: 179
-
OPENTitle: Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson’s Disease in RodentsJournal Name: Journal of Parkinson’s DiseasePublisher: SAGE PublicationsVol: 8Issue #: 2Start Page: 303End Page: 322Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-171248Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd171248?id=journal-of-parkinsons-disease%2Fjpd171248Citation Count: 308
- Crossroads in GDNF therapy for Parkinson's disease2006RESTRICTEDTitle: Crossroads in GDNF therapy for Parkinson's diseaseJournal Name: Movement DisordersPublisher: WileyVol: 21Issue #: 2Start Page: 136End Page: 141Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.20861Citation Count: 174
-
OPENTitle: Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinaseJournal Name: Biochemical JournalPublisher: Portland Press Ltd.Vol: 475Issue #: 1Start Page: 1End Page: 22Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1042/bcj20170802Best OA location URL: https://portlandpress.com/biochemj/article-pdf/475/1/1/694077/bcj-2017-0802.pdfCitation Count: 166